Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash from Operations (2018 - 2025)

BioNexus Gene Lab's Cash from Operations history spans 8 years, with the latest figure at 1237465.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 22.8% year-over-year to 1237465.0; the TTM value through Sep 2025 reached 2721241.0, up 12.08%, while the annual FY2024 figure was 2234260.0, 22.61% down from the prior year.
  • Cash from Operations for Q3 2025 was 1237465.0 at BioNexus Gene Lab, down from 737907.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 483007.0 in Q4 2021 and bottomed at 1603035.0 in Q3 2024.
  • The 5-year median for Cash from Operations is 116518.0 (2023), against an average of 331312.26.
  • The largest annual shift saw Cash from Operations soared 111.81% in 2021 before it tumbled 2721.96% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 483007.0 in 2021, then dropped by 1.3% to 476739.0 in 2022, then crashed by 264.14% to 782526.0 in 2023, then soared by 109.99% to 78203.0 in 2024, then plummeted by 1682.38% to 1237465.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Cash from Operations are 1237465.0 (Q3 2025), 737907.0 (Q2 2025), and 824072.0 (Q1 2025).